Cieri, Nicoletta http://orcid.org/0000-0003-1340-6272
Hookeri, Nidhi
Stromhaug, Kari
Li, Liang
Keating, Julia
Díaz-Fernández, Paula
Gómez-García de Soria, Valle
Stevens, Jonathan
Kfuri-Rubens, Raphael http://orcid.org/0000-0003-3256-9640
Shao, Yiren
Kooshesh, Kameron A.
Powell, Kaila
Ji, Helen
Hernandez, Gabrielle M. http://orcid.org/0009-0005-0494-0467
Abelin, Jennifer
Klaeger, Susan http://orcid.org/0000-0002-0074-5163
Forman, Cleo
Clauser, Karl R. http://orcid.org/0000-0002-1052-9456
Sarkizova, Siranush http://orcid.org/0000-0003-2530-8610
Braun, David A. http://orcid.org/0000-0003-4543-5553
Penter, Livius http://orcid.org/0000-0002-9060-0207
Kim, Haesook T.
Lane, William J. http://orcid.org/0000-0002-1097-5229
Oliveira, Giacomo http://orcid.org/0000-0001-7435-5603
Kean, Leslie S.
Li, Shuqiang http://orcid.org/0000-0001-9106-6141
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Carr, Steven A. http://orcid.org/0000-0002-7203-4299
Keskin, Derin B. http://orcid.org/0000-0002-8496-6181
Muñoz-Calleja, Cecilia
Ho, Vincent T.
Ritz, Jerome http://orcid.org/0000-0001-5526-4669
Soiffer, Robert J.
Neuberg, Donna http://orcid.org/0000-0003-2566-3145
Stewart, Chip
Getz, Gad http://orcid.org/0000-0002-0936-0753
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Article History
Received: 10 July 2023
Accepted: 2 July 2024
First Online: 21 August 2024
Competing interests
: C.J.W. holds equity in BioNTech and receives research support from Pharmacyclics. D.B.K is a scientific advisor for Immunitrack and Breakbio and owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Celldex Therapeutics, Editas Medicine, Gilead Sciences, Immunitybio, IMV, Lexicon Pharmaceuticals and Neoleukin Therapeutics. BeiGene supported unrelated SARS-COV-2 research at Translational Immunogenomics Lab. R.J.S. consults or is on the advisory board of Kiadis, Juno Therapeutics, Gilead, Jasper, Jazz Pharmaceuticals, Precision Biosciences, Rheo Therapeutics, Takeda and NMDP—Be the Match. J.R. receives research funding from Kite/Gilead, Novartis and Oncternal and consults or is on advisory boards for Clade Therapeutics, Garuda Therapeutics, LifeVault Bio, Smart Immune and TriArm Bio. V.T.H. receives funding from Jazz Pharmaceuticals and consults or is on advisory boards for Jazz Pharmaceuticals, Janssen, Alexion Pharmaceuticals and Omeros. W.J.L. consults or is on the advisory board of CareDx, One Lambda and Thermo Fisher Scientific and receives royalty payments from Thermo Fisher Scientific. K.J.L. holds equity in Standard BioTools and is on the scientific advisory board for MBQ Pharma. S.A.C. is a member of the scientific advisory boards of PTM BioLabs, Kymera, Seer and PrognomIQ and holds equity in the latter three. D.A.B. reports honoraria from LM Education/Exchange Services; advisory board fees from Exelixis and AVEO; personal fees from Schlesinger Associates, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie, DLA Piper and Elephas; equity in CurIOS Therapeutics, Elephas and Fortress Biotech (subsidiary); research support from Exelixis (US) and AstraZeneca (UK), outside of the submitted work. G.O. is a consultant for Bicycle Therapeutics. L.S.K. is on the scientific advisory board for Mammoth Biosciences and HiFiBio; received research funding from Magenta Therapeutics, Tessera Therapeutics, Novartis, EMD Serono, Gilead Pharmaceuticals and Regeneron Pharmaceuticals; consulting fees from Vertex; grants/personal fees from Bristol Myers Squibb and royalties/partial funding for the current study from Bristol Myers Squibb. L.S.K.’s conflict of interest with Bristol Myers Squibb is managed under an agreement with Harvard Medical School. D.N. holds equity in Madrigal Pharmaceutics. G.G. receives research funds from Pharmacyclics, Ultima Genomics and IBM. G.G. receives research funds from Pharmacyclics, Bayer, Genentech, Ultima Genomics and IBM; is an inventor of patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER, SignatureAnalyzer-GPU and MinimuMM-seq; is a founder and consultant and holds privately held equity in Scorpion Therapeutics and is a founder and holds privately held equity in PreDICTA Biosciences. The other authors declare no competing interests.